BiotechTube

QL1706 + Gemcitabine + Cisplatin

Phase 3Recruiting
0 views this week 0 watching⚡ Active
Interest: 47/100
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Nasopharyngeal Cancinoma (NPC)

Conditions

Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer

Trial Timeline

May 4, 2025 → Dec 1, 2030

NCT ID
NCT06749899

About QL1706 + Gemcitabine + Cisplatin

QL1706 + Gemcitabine + Cisplatin is a phase 3 stage product being developed by Sun Pharmaceutical for Nasopharyngeal Cancinoma (NPC). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06749899. Target conditions include Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer.

What happened to similar drugs?

0 of 12 similar drugs in Nasopharyngeal Cancinoma (NPC) were approved

Approved (0) Terminated (0) Active (12)
🔄CisplatinSun PharmaceuticalPhase 3
🔄Cisplatin 1 + Cisplatin 2 + Docetaxel + XelodaSun PharmaceuticalPhase 3
🔄5-fu + Lobaplatin + Placebo + leucogenSun PharmaceuticalPhase 3
🔄CapecitabineSun PharmaceuticalPhase 3
🔄Nedaplatin + CisplatinSun PharmaceuticalPhase 3
🔄PD-1 blocking antibody + Gemcitabine + Cisplatin (80 mg/m2) + Cisplatin (100 mg/m2) + CapecitabineSun PharmaceuticalPhase 3
🔄docetaxel, nedaplatin, and capecitabine + nedaplatin + docetaxel, cisplatin, and fluorouracil + cisplatin + docetaxel, cisplatin, and capecitabine + docetaxel, nedaplatin, and fluorouracilSun PharmaceuticalPhase 3

Hype Score Breakdown

Clinical
17
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06749899Phase 3Recruiting

Competing Products

20 competing products in Nasopharyngeal Cancinoma (NPC)

See all competitors
ProductCompanyStageHype Score
Nanatinostat + Valganciclovir + PembrolizumabViracta TherapeuticsPhase 1
11
Cisplatin 2 + Docetaxel + Cisplatin 1Sun PharmaceuticalPhase 2
31
CisplatinSun PharmaceuticalPhase 3
36
Cisplatin 1 + Cisplatin 2 + Docetaxel + XelodaSun PharmaceuticalPhase 3
36
5-fu + Lobaplatin + Placebo + leucogenSun PharmaceuticalPhase 3
47
CapecitabineSun PharmaceuticalPhase 3
36
Amifostine every-other-day regimen + Amifostine everyday regimenSun PharmaceuticalPhase 2
31
Nedaplatin + CisplatinSun PharmaceuticalPhase 3
40
PD-1 blocking antibody + Gemcitabine + Cisplatin (80 mg/m2) + Cisplatin (100 mg/m2) + CapecitabineSun PharmaceuticalPhase 3
47
The combination treatment of anlotinib, penpulimab and capecitabine.Sun PharmaceuticalPhase 2
39
docetaxel, nedaplatin, and capecitabine + nedaplatin + docetaxel, cisplatin, and fluorouracil + cisplatin + docetaxel, cisplatin, and capecitabine + docetaxel, nedaplatin, and fluorouracilSun PharmaceuticalPhase 3
47
Pemetrexed (Alimta)Eli LillyPhase 2
35
Camrelizumab + Placebos + Gemcitabine + CisplatinJiangsu Hengrui MedicinePhase 3
36
Famitinib + CisplatinJiangsu Hengrui MedicinePhase 1
29
SHR-1210 + Gemcitabine + cis-platinumJiangsu Hengrui MedicinePhase 1
29
SHR-1701 + Gemcitabine + Cisplatin + Albumin PaclitaxelJiangsu Hengrui MedicinePhase 1
25
FamitinibJiangsu Hengrui MedicinePhase 2
35
ApatinibJiangsu Hengrui MedicinePhase 2
35
SHR-1210Jiangsu Hengrui MedicinePhase 2
35
SHR-1701 + FamitinibJiangsu Hengrui MedicinePhase 1/2
28